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Abstract: The paradigm for the treatment of monoclonal gammopaties has dramatically 
changed: therapeutic options in multiple myeloma (MM) have evolved from the introduction 
of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplan-
tation in the late 1980s and 1990s, to the rapid introduction of small novel molecules within 
the last seven years. Based on the understanding of the complex interaction of the MM cells 
with the bone marrow microenvironment and the signaling pathways that are dysregulated in 
this process, a number of novel therapeutic agents are now available. Speciﬁ  cally, three novel 
agents with a speciﬁ  c-targeted anti-MM activity, have been FDA-approved for the treatment 
of this disease, namely Bortezomib, thalidomide, and lenalidomide which are now all playing 
a key role in the treatment of MM. The success of targeted therapy in MM has since led to the 
development and investigation of more than 30 new compounds in this disease and in other 
plasma cell dyscrasias such as Waldenström’s macroglobulinemia and primary amyloidosis, 
both in the preclinical settings and as part of clinical trials.
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Introduction
Monoclonal gammopaties represent a clinically heterogeneous group of diseases 
generally considered plasma cell dyscrasias and characterized by abnormal production 
of monoclonal (M) immunoglobulin, also called M-protein or M-component, produced 
by a clone that developed from a common progenitors in the B lymphocyte lineage. 
The M-component may be detected by electrophoresis as a band of resctricted migra-
tion in the serum or urine. They include monoclonal gammophaty of undetermined 
signiﬁ  cance (MGUS), multiple myeloma (MM), Waldenström’s macroglobulinemia 
(WM), primary (AL) amyloidosis, heavy chain diseases, cryoglobulinemia type I and 
type II, and other lymphoproliferative disorders.
In this review, the role of new targeted therapies available for monoclonal gam-
mopaties will be discussed, focusing on MM, WM, and amyloidosis.
After almost forty years, the paradigm for the treatment of monoclonal gammopaties 
has dramatically changed: for example, therapeutic options in MM have evolved from 
the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy 
and stem cell transplantation in the late 1980s and 1990s, to the rapid introduction 
of small novel molecules within the last seven years. Based on the understanding of 
the complex interaction of the MM cells with the bone marrow (BM) microenviron-
ment and the signaling pathways that are dysregulated in this process, a number of 
novel therapeutic agents are now available. Speciﬁ  cally, three novel agents with a 
speciﬁ  c-targeted anti-MM activity, have been US Food and Drug Administration Biologics: Targets & Therapy 2008:2(3) 420
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(FDA)-approved for the treatment of this disease, namely 
Bortezomib, thalidomide, and lenalidomide which are now 
all playing a key role in the treatment of MM. The success 
of targeted therapy in MM has since led to the development 
and investigation of more than 30 new compounds in this 
disease and in WM, both in the preclinical settings and as 
part of clinical trials.
Immunomodulatory drugs (IMiDs): 
thalidomide and lenalidomide
Thalidomide
Thalidomide was ﬁ  rst used as a sedative and hypnotic drug 
in the 1950’s. It was withdrawn from the market because 
of its teratogenic effects. In 1999 a phase II study showed 
that thalidomide, used as a single agent in patients with 
relapsed MM, resulted in an overall response rate (ORR) of 
25% (Singhal et al 1999). The main activity and efﬁ  cacy of 
thalidomide in MM was then elucidated. It has been shown 
that thalidomide induces in vitro growth arrest, blocks the 
increased secretion of tumor necrosis factor alpha (TNF-α), 
and affects the interaction between myeloma cells and BM 
microenvironment by decreasing the expression of adhesion 
molecules (E-selectin, L-selectin, ICAM-1, VCAM-1) or 
inhibiting the paracrine loops of cytokine secretion, such as 
vascular endothelial growth factor (VEGF) and interleukin 
(IL)-6; inhibits angiogenesis; and enhances host immune 
response against MM; interferes with intracellular growth 
signalling by inhibiting the constitutive activity of nuclear 
factor kappa B (NFkB) (Hideshima et al 2000; Davies et al 
2001; Mitsiades et al 2002) (Figure 1). Several studies then 
tested the combination of thalidomide with other agents such 
as dexamethasone and chemotherapeutic drugs in patients 
with relapsed/refractory MM, and this led to response rates as 
high as 65% (Rajkumar et al 2000, 2002; Weber et al 2003; 
Kumar et al 2006). After these encouraging results, thalido-
mide in combination with dexamethasone entered several 
phase II clinical trials in newly diagnosed MM patients, and 
demonstrated a RR of ∼ 65% (Rajkumar et al 2002; Weber 
et al 2003a; Kumar and Rajkumar 2006). Subsequently, a 
large phase III clinical trial was performed using thalidomide 
with dexamethasone versus high-dose dexamethasone alone 
for newly diagnosed MM patients, resulting in a 63% RR 
in the thalidomide/dexamethasone arm versus 41% in the 
dexamethasone arm, although no survival advantage was 
observed between the two groups (Rajkumar et al 2006).
Other phase III trials in elderly patients who were not 
candidates for autologous stem cells transplant included 
a randomized study compared melphalan prednisone and 
thalidomide (MPT) versus melphalan and prednisone 
(MP), which showed that patients treated with MPT had 
higher RR (76% versus 48%) and longer event-free survival 
(EFS) than patients treated with MP alone (54% versus 
27%) (Palumbo et al 2006). Facon and colleagues (2006) 
conducted a large phase III trial of MPT compared to MP 
or high dose chemotherapy and stem cell transplantation in 
elderly patients between 65 to 75 years of age and showed 
that patients treated with MPT had a longer overall survival 
of 54 months compared to 32 months for MP and 39 months 
for transplant.
A randomized study has recently investigated the activity 
of thalidomide in combination with VAD and doxil, com-
pared to VAD-doxil and it resulted in a higher RR in the arm 
with thalidomide versus the arm without thalidomide (81% 
versus 66%) (Zervas et al 2006). The toxicities of thalidomide 
correlate both with dose and length of treatment and include 
neuropathy and deep vein thrombosis. Other important toxici-
ties include fatigue, somnolence, constipation, rash (includ-
ing Stevens-Johnson syndrome), and hepatic dysfunction 
(Ghobrial and Rajkumar 2003).
In view of its success in the treatment of patients with 
MM, thalidomide has been tested alone in WM patients, 
demonstrating partial response in 25% of patients treated 
with single-agent thalidomide. Adverse effects were com-
mon and prevented dose escalation of thalidomide in 75% 
of patients. In addition, thalidomide in combination with 
dexamethasone and clarithromycin induced partial response 
in 10 of 12 (83%) previously treated patients (Dimopoulos 
et al 2003). However, a follow up study of 10 patients with 
higher doses of thalidomide (200 mg daily) showed only 20% 
overall response rate (Treon et al 2006a). Several clinical 
trials using thalidomide in combination with a wide variety 
of other compounds are ongoing in patients with MM and 
WM (Table 1).
High-dose chemotherapy has increased the response 
rate in patients with MM, but this therapeutical option is 
not curative and an effective consolidation-maintenance 
could extend the duration of response. Several studies 
have evaluated the role of maintenance therapy with 
thalidomide in MM patients after autologous stem-cell 
transplantation, which shows that thalidomide improves 
survival and represents a valid and effective strategy as a 
maintenance therapy option (Attal et al 2006; Abdelkeﬁ   et al 
2007; Spencer et al 2007).
Finally, thalidomide has been evaluated also in AL 
amyloidosis patients where it induced response rates up to Biologics: Targets & Therapy 2008:2(3) 421
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50% when combined with dexamethasone. Unfortunately, 
the regimen is poorly tolerated, with 50%–65% of 
patients experiencing grade 3 or 4 toxicities (Palladini 
et al 2005).
Lenalidomide
Based on the success of thalidomide, lenalidomide (CC-5013; 
IMiD-3, Celgene Corp), a more potent immunomodulatory 
derivative of thalidomide was developed. Lenalidomide 
overcomes growth and survival advantage conferred by the 
BM-milieu, downregulates VEGF, and exerts antiangiogenic 
activities. In addition, lenalidomide co-stimulates T cells, 
enhances antitumor immunity mediated by interferon (IFN)γ 
and IL-2, and augments natural killer (NK) cell cytotoxicity 
(Hideshima et al 2001; Mitsiades et al 2002; Dredge et al 
2002) (Figure 1).
Table 1 Ongoing clinical trials using thalidomide-based regimens in MM and WM (www.clinicaltrials.gov)
Treatment regimen Disease Phase Endpoints
Thal+Bort MM/refractory I Toxicities
Thal+Dex vs Doxil+Thal+Dex MM/newly diagnosed III ORR, OS
Thal+Clarithromycin+Len+ Dex MM/relapsed refractory II Safety, efﬁ  cacy
Thal+Doxorubicin+Dex MM/untreated stage II/III II ORR, safety, toxicity
Thal+/-Lenal+Dex MM III ORR, toxicity
Thal+Bort MM/newly diagnosed stage II/III II Tumor response, mobilization/
collection stem cells, incidence/
severity of neuropathy
Thal+Doxil+Bort MM/untreated stage I/II/III II ORR, TTP
Thal+AsO3+ascorbic acid+ Dex MM/relapsed, refractory I Toxicity, safety, tolerability
Thal+Oblimersen+Dex MM/relapsed, refractory II ORR
Thal+Bort+CTX+Dex MM/untreated II ORR, safety, tolerability
Thal+Riuximab WM II ORR, TTF, toxicity
Abbreviations: Thal, thalidomide; Bort, Bortezomib; Doxil, liposomal doxorubicine; Len, lenalidomide; Dex, dexamethasone; CTX, cyclophosphamide; AsO3, arsenic trioxide; 
Mel, melphalan; Pdn, prednisone; ORR, overall response rate; OS, overall response; TTP, time to progression; PFS, progression-free survival; TTF, time to treatment failure.
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Figure 1 Mechanisms of action of novel agents. Novel molecules can:  I) directly inhibit clonal cells;  II) inhibit angiogensis;  III) inhibit tumor cell adhesion to bone marrow stromal 
cells (BMSCs);  IV) decrease cytokine production from BMSCs;   V) increase host anti-tumor immunity.Biologics: Targets & Therapy 2008:2(3) 422
Roccaro et al
Phase I clinical trials using lenalidomide in patients with 
relapsed and refractory MM, established a dose of 25 mg, 
and demonstrated a promising RR of 35% (Richardson et al 
2006a). Phase II studies followed and established the optimal 
schedule of 3 weeks on and 1 week off with once daily dosing 
(Richardson et al 2001, 2006b).
Then, two large randomized phase III studies (MM-009, 
MM-010) compared lenalidomide and dexamethasone to 
dexamethasone and placebo for patients with relapsed or 
relapsed and refractory MM. They both showed compara-
bly favorable results, with RR and time to progression with 
the lenalidomide/dexamethasone combination signiﬁ  cantly 
greater and more than twice the RR seen with dexamethasone 
alone (Dimopoulos 2005a; Weber et al 2006).
Based upon the success of these studies, lenalidomide 
received FDA-approval for the treatment of relapsed MM in June 
2006. A phase II study of the combination of lenalidomide and 
dexamethasone was performed in 32 newly diagnosed patients 
with MM and showed an ORR of 91% (Rajkumar et al 2005). 
A recent study demonstrated the efﬁ  cacy of lenalidomide in 
combination with melphalan and prednisone which was associ-
ated with a RR of 86% (Palumbo et al 2006). Similarly, the com-
bination of lenalidomide with other drugs such as adriamycin 
and dexamethasone showed a RR of 84% (Knop et al 2006).
A Phase III clinical trial using lenalidomide in combina-
tion with dexamethasone in newly diagnosed MM patients 
has been recently completed and showed that lenalidomide 
plus low-dose dexamethasone is associated with superior OS 
compared to lenalidomide plus high-dose dexamethasone 
(Rajkumar et al 2007). The main side effects of lenalidomide 
include myelosuppression, particularly neutropenia and 
thrombocytopenia, and deep venous thrombosis especially 
when it used in combination with high-dose dexamethasone 
(Rajkumar and Blood 2006).
Based on the potent activity of lenalidomide in MM and 
considered the lack of neuropathy with this agent, a phase 
II study of lenalidomide 25 mg daily in combination with 
rituximab is ongoing in patients with relapsed or relapsed/
refractory WM.
More than forty clinical trials using lenalidomide in 
combination with several other compound are actually on 
going in patients with MM and WM (Table 2).
Lenalidomide has also entered a phase II clinical trials 
for patients with AL amyloidosis. When combined with 
dexamethasone, lenalidomide induced response rates of 
nearly 67%, with 29% of hematologic complete response 
(Sanhorawala et al 2007).
Proteasome inhibitors: Bortezomib 
and second-generation (NPI-0052; 
PR171)
Bortezomib
Bortezomib (PS-341, Millennium Pharmaceuticals, Inc) 
represents the ﬁ  rst in class proteasome inhibitor to have 
progressed into widespread clinical use in MM patients, 
based on preclinical data showing its in vitro and in vivo 
anti-tumor activity in MM cells, by inhibiting proliferation, 
inducing apoptosis and by targeting the BM microenviron-
ment through its antiangiogenic activity and by inhibiting 
the binding of MM cells to the BM stromal cells (Figure 1). 
Bortezomib as single agent has been evaluated in patients 
with advanced, heavily pretreated MM in the SUMMIT 
study (Study of Uncrontrolled Multiple Myeloma managed 
Table 2 Ongoing clinical trials using lenalidomide-based regimens in MM and WM (www.clinicaltrials.gov)
Treatment regimen  Disease  Phase  Endpoints
Len+Doxorubicine+Dex  MM/relapsed, refractory  I/II  Safety, efﬁ  cacy, ORR
Len+Mel+Pdn vs high-dose Mel  MM/newly diagnosed  III  PFS, ORR, OS
Len+Bort+Dex vs   MM/untreated  I/II  ORR
Len+Bort+Dex+CTX
Len+Dex+Thal  MM/Dex previously treated  III  PFS, ORR, OS
Len+Dex+Thal MM/relapsed,  refractory  II  Efﬁ  cacy, safety
Len+Perifosine+Dex  MM  I  Safety, adverse events
Len+SGN-40+Dex MM  I  safety
Len+Dex vs Dex  MM/previously treated  III  TTP, OS
Len+Mel+Pdn  MM/untreated patients  I/II  Toxicity, TTP, OS, ORR
Len+Mel  MM/untreated patients  II  Toxicity, tumor response, 
      TTP, OS, DFS
Len+Rituximab WM  II  ORR,  TTP,  safety
Abbreviations: Len, lenalidomide; Dex, dexamethasone; Mel, melphalan; Pdn, prednisone; Bort, Bortezomib; CTX, cyclophosphamide; Thal, thalidomide; ORR, overall response 
rate; PFS, progression-free survival; OS, overall survival; TTP: time to progression; DFS, disease-free survival.Biologics: Targets & Therapy 2008:2(3) 423
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with proteasome Inhibition Therapy) (Richardson et al 2003) 
which showed an ORR of 35% in 202 patients with relapsed 
and refractory MM. The CREST (Clinical Response and Efﬁ  -
cacy Study of Bortezomib in the Treatment of myeloma) trial, 
a phase II study randomizing patients to higher (1.3 mg/m3) or 
lower (1.0 mg/m3) doses of Bortezomib in combination with 
dexamethasone, revealed positive response rates (33% with 
low-dose Bortezomib alone, 44% with low-dose Bortezo-
mib/dexamethasone, 50% with high-dose Bortezomib, and 
62% with high-dose Bortezomib/dexamethasone) (Jagannath 
et al 2004). Subsequently, the APEX study (Assessment of 
Proteasome Inhibition for Extending Remission) compared 
Bortezomib with high-dose dexamethasone in patients with 
relapsed/refractory MM, and showed an ORR of 38% in the 
Bortezomib arm, versus 18% obtained in the high-dose dexa-
methasone. Moreover, Bortezomib demonstrated superiority 
over dexamethasone in terms of time to progression and 
survival (Richardson et al 2005a). Based on these encourag-
ing data, Bortezomib was FDA-approved in 2003 with full 
approval in 2005 and numerous trials using Bortezomib in 
combination with other agents were built.
Other combinations included chemotherapies and novel 
agents (Richardson et al 2006c). The combination of Bort-
ezomib, thalidomide and dexamethasone (VTD) in patients 
with relapsed MM showed an overall response rate of 70% 
including near complete responses in 16%. High responses 
were also observed in studies of patients with previously 
untreated MM. Single agent Bortezomib showed an overall 
response rate of 40% with 10% complete responses in a phase 
II study of 66 patients with MM.
The combination of Bortezomib and dexamethasone 
led to an overall response rate of 66% to 88% in another 
phase II trial of newly diagnosed MM (Jagannath et al 2006; 
Harousseau et al 2006).
In addition, the combination of Bortezomib (V), 
melphalan (M) and prednisone (P) (MPV) in nontransplant 
candidates resulted in an overall response rate of 89% 
(Mateos et al 2007). Interestingly, a phase III trial random-
izing newly diagnosed MM patients to either VMP or MP, has 
been recently completed and showed that VMP signiﬁ  cantly 
prolongs survival and is superior for all efﬁ  cacy endpoints: 
speciﬁ  cally VMP induced rapid and durable responses with 
unprecedented complete response rate (35%); prolonged time 
to progression (∼52% reduced risk of progression), time to 
next therapy/treatment free interval; and overall survival 
(∼40% reduced risk of death) (San Miguel et al 2007).
Also the combination of Bortezomib, dexamethasone, 
and cyclophosphamide was shown to be more effective 
than Bortezomib either used as single agent or with 
dexamethasone (Davies et al 2006). These encouraging 
results were subsequently confirmed by a multicenter 
randomized phase 3 study comparing the combination of 
doxil and Bortezomib versus Bortezomib alone (Orlowski 
et al 2006). Similarly it has been recently demonstrated that 
liposomal doxorubicin+Bortezomib signiﬁ  cantly improves 
TTP compared to Bortezomib alone, regardless of the number 
of prior lines of therapy, or anthracycline exposure (Blade 
et al 2007).
Based on its activity in MM, single agent Bortezomib 
was tested in WM in phase II trials and achieved 40%–80% 
responses (Dimopoulos et al 2005b). The combination of 
Bortezomib, dexamethasone and rituximab was recently 
evaluated in untreated patients with WM. Each cycle of 
therapy consisted of IV Bortezomib at 1.3 mg/m2 and IV 
dexamethasone 40 mg on days (1, 4, 8, and 11), and rituximab 
at 375 mg/m2 (day 11). Patients received four consecutive 
cycles, followed by a three-month pause, and then 4 more 
cycles, each given three months apart. The interim analysis of 
the ﬁ  rst 10 patients who received the ﬁ  rst 4 cycles of therapy 
showed partial response in 50% and minor response in the 
other 50%, with 2 patients (20%) achieving an unconﬁ  rmed 
complete response (Treon et al 2006b).
There are actually several clinical trials ongoing using 
Bortezomib either alone or in combination with other agents 
in MM and WM patients (Table 3).
Recently the role of proteasome inhibition has been stud-
ied in AL amyloidosis, characterized by the overproduction 
of a destabilized light chain which tends to aggregate and 
deposit in several tissues (Sitia et al 2007; Kastritis et al 
2007). The process of amyloid deposition induces tissue 
damage and subsequently organ failure, leading to high 
mortality. The combination of Bortezomib and dexametha-
sone has been successfully evaluated in patients with AL 
amyloidosis who were relapsed or progressed after previ-
ous thalidomide-based treatments, and who were ineligible 
for high-dose melphalan supported by autologous stem cell 
transplantation: 94% hematologic responses were observed, 
including 44% complete responses.
New proteasome inhibitor, NPI-0052
Based on the signiﬁ  cant anti-MM activity of Bortezomib, a 
new proteasome inhibitor (NPI-0052; Nereus Pharmaceuti-
cals, CA) with a different structure and different mechanism 
of action has been developed. NPI-0052 is an oral protea-
some inhibitor that has shown signiﬁ  cant anti-neoplastic 
activity in MM and WM (Chauhan et al 2005). Importantly, Biologics: Targets & Therapy 2008:2(3) 424
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the combination of NPI-0052 and Bortezomib induced sig-
niﬁ  cant inhibition of proliferation compared to each agent 
alone (Chauhan et al 2007; Roccaro et al 2008). A phase I 
clinical trial of NPI-0052 in relapsed MM has recently been 
initiated.
PR-171
PR-171 is a novel irreversible proteasome inhibitor under 
investigation for the treatment of hematological malignan-
cies. Two phase I dose-escalation studies have been initiated, 
aimed at determining the safety, tolerability, and clinical 
response to PR-17 (O’Connor et al 2006). Patients with mul-
tiple myeloma, non-Hodgkin lymphoma, Hodgkin disease, or 
Waldenström macroglobulinemia who received two or more 
prior treatments were eligible. Two different dose-intensive 
schedules were employed in these phase I studies. PR-171 
was well-tolerated, and several subjects have achieved long-
lasting SD, reduction in paraprotein levels, or symptomatic 
improvement (O’Connor et al 2006).
Signaling pathway inhibitors
Preclinical data have been demonstrated that monoclonal 
gammopaties are characterized by disregulation of several 
signalling pathways, as compared to normal plasma cells 
(Hideshima et al 2004a; Hatjiharissi et al 2007; Leleu et al 
2007). Moreover there is strong evidence that BM-milieu 
supports the growth of the clonal cell population. Therefore, 
this important knowledge has led to the development of 
several agents that speciﬁ  cally target the neoplastic clone 
by acting through those upregulated signaling pathways, the 
Table 3 Ongoing clinical trials using Bortezomib-based regimens in MM and WM (www.clinicaltrials.gov)
Treatment regimen Disease Phase Endpoints
Bort + Perifosine +/− Dex MM/relapsed, refractory, previously 
treated with Bortezomib
I/II Toxicity, ORR
Bort + CCI-779 MM/relapsed, relapsed/refractory I/II Safety, MTD, TTP, PFS, OS
Bort+Doxil+Dex followed by 
Thal+Dex +/− Bort
MM II Toxicity, disease response
Bort+Sorafenib MM/relapsed, refractory I/II ORR, PFS
Bort+Doxil+Mel MM/relapsed, refractory I/II Safety , tolerability, MTD
Bort+Doxil MM II ORR, toxicity, OS, PFS, TTP
Bort+AsO3+Vitamin C MM I/II Safety, toxicity,
Bort+Samarium153 MM/relapsed, refractory I Toxicity, MTD, TTP, PFS, OS
Bort+Vorinostat (SAHA) MM/relapsed, refractory I MTD, toxicity
Bort+Ascorbic Acid+Mel MM/newly diagnosed II Safety, tolerability, ORR, TTP, TTR, 
PFS, OS
Bort+Dex+Doxil followed by CTX MM/post ﬁ  rst line therapy; 
relapsed/refractory Bortezomib 
naïve
II Efﬁ  cacy, safety
Bort+Thal+Dex MM/relapsed, refractory II ORR, OS, PFS, toxicity
Bort+Dex+Thal vs 
Bort+Dex+Thal+CTX
MM/newly diagnosed candidate for 
high-dose therapy and stem cell 
transplantation
II ORR, TTP, PFS
Bort WM II ORR, safety, tolerability
Bort+Rituximab WM/relapsed, refractory II ORR, safety, TTP
Bort+Rituximab WM/newly diagnosed II ORR, ability to collect stem cells, 
ORR, TTP, toxicity
Bort+Thal+Dex vs Bort+Dex vs 
Bort+Mel+Pdn
MM/untreated III PFS
Bort+Thal+Dex +/−Adriamycin MM/relapsed, refractory III Efﬁ  cacy, toxicity
Bort+Dex+Rituximab WM II Safety, tolerability, ORR, TTP
Bort WM/untreated or relapsed II Toxicity, ORR, TTP, stable disease 
duration, response duration
Abbreviations: Bort, Bortezomib; Dex, dexamethasone; Doxil, liposomal doxorubicine; Thal, thalidomide; CTX, cyclophosphamide; Mel, melphalan; AsO3, arsenic trioxide; 
ORR, overall response rate; MTD, maximum tolerated dose; TTP, time to progression; PFS, progression-free survival; OS, overall response.Biologics: Targets & Therapy 2008:2(3) 425
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BM microenvironment, are able to affect both the clonal cells 
and the BM-milieu (Hideshima et al 2006).
Signaling pathway inhibitors active 
in both MM and WM
Akt inhibitor: perifosine
Perifosine (NCS-639966; Keryx Biopharmaceuticals, Inc) 
is an orally-active alkyl-phosphocholine molecule that 
affects membrane permeability; phospholipid metabolism; 
as well as mitogenic signaling transduction induced by 
the PI3/Akt pathway (Hideshima et al 2006). It has been 
recently demonstrated that perifosine has in vitro and in vivo 
activity against MM and WM cell lines and patient primary 
tumor cells, even in presence of BM stromal cells which are 
known to support tumor cell growth and induce resistance 
to apoptosis. In addition, perifosine showed synergistic 
activity when used in combination with other agents widely 
used in MM and WM such as dexamethasone, Bortezomib, 
doxorubicin, melphalan, and rituximab, speciﬁ  cally for MM 
and WM, respectively (Hideshima et al 2006; Leleu et al 
2007). A phase II clinical trial of perifosine with or without 
dexamethasone in patients with relapsed and refractory MM 
has recently reported and showed activity, with 69% of 
patients achieving response and/or stabilization of disease 
(Richarson et al 2006d).
Another phase II trial of the combination of perifosine 
with Bortezomib ± dexamethasone is currently underway 
in MM patients. Similarly, a phase II trial of single agent 
perifosine in patients with relapsed or relapsed/refractory 
WM has been initiated using 150 mg oral daily dosing. The 
preliminary data of 13 patients enrolled on the study, with a 
median follow up time of 3 months, demonstrated promising 
activity of this agent. The treatment was well tolerated with 
minimal side effects. Seven patients were evaluable at the 
time of analysis and all showed evidence of IgM reduction, 
with a median IgM reduction of 14% (0%–25%). One patient 
whose IgM rose in the ﬁ  rst month had a 50% reduction from 
the peak of IgM level at 3 months, indicating a delayed 
response. These preliminary results indicate that perifosine is 
a promising agent to be used in combination in future studies 
both in MM and WM.
Protein kinase C inhibitor: enzastaurin
Enzastaurin[H-Pyrrole-2,5-dione,3-(1-methyl-1H-indol-
3-yl)-4-[1-[-1(2pyridinylmethyl)-4-piperidinyl]-1H-indol-
3-yl], LY 317615; Eli Lilly and company, (Indianapolis, IN) 
is an oral PKCβ inhibitor, with downstream inhibition of Akt 
(Podar et al 2006). In MM, enzastaurin has demonstrated 
speciﬁ  c inhibition of PKC isoforms and Akt activation along 
with inducing cytotoxicity and apoptosis in MM and WM 
cells in vitro and in vivo (Podar et al 2006; Moreau et al 
2007). Synergism has been demonstrated when enzastaurin 
was used in combination with Bortezomib. In addition, 
enzastaurin inhibted MM and WM cell growth in an in vivo 
xenograft model of these diseases. Based on these exciting 
preclinical data, enzastaurin alone and in combination with 
Bortezomib entered clinical trials in MM, and phase II trial 
are planned in WM as single agent.
Mammalian target of rapamycin inhibitors: 
CCI-779, RAD001
mTOR inhibitors such as rapamycin and rapamycin ana-
logues including CCI-779 and RAD001 have demonstrated in 
vitro and in vivo activity in MM cell lines and animal model 
(Shi et al 2002; Mitsiades et al 2004). The combination of 
rapamycin with active agents in MM such as lenalidomide, 
Bortezomib and 17-AAG have demonstrated synergistic 
activity in vitro (Raje et al 2004; Francis et al 2006). In addi-
tion, rapamycin appears to target the BM microenvironment 
by inhibiting angiogenesis and osteoclast formation in MM 
in vitro (Francis et al 2006). Similarly, Preclinical data have 
demonstrated increased activity of the PI3K/mTOR pathway 
in WM, and subsequently rapamycin (mTOR inhibitor) has 
been studied in vitro in WM and showed signiﬁ  cant cyto-
toxicity in WM cells lines, speciﬁ  cally when combined with 
Bortezomib (unpublished data).
These ﬁ  ndings have led to the design of studies using 
these agents in combination with other active agents in 
MM and WM. A phase II trial of RAD-001 in combination 
with lenalidomide, and a phase I/II clinical trial of CCI-779 
in combination with Bortezomib are underway in patients 
with relapsed/refractory MM. In addition, a phase II trial of 
single agent RAD001 was initiated in aggressive, low grade 
lymphomas, and rare lymphomas including WM.
Signaling pathway inhibitors active 
in MM
MEK/ERK inhibitor: AZD-6244
AZD6244 (AstraZeneca, Los Angeles, CA) has been tested 
in preclinical models in MM and induced inhibition of 
growth and cytotoxicity in MM cells even in the presence 
of cytokines/growth factors such as IL-6, IGF-1 that induce 
MEK/ERK activation (Hu et al 2003; Hideshima et al 2004a). 
A phase II trial of single agent AZD6244 is planned in 2007 
for patients with relapsed/refractory MM.Biologics: Targets & Therapy 2008:2(3) 426
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p38MAPK inhibitor: SCIO-469
SCIO-469 (Scios, Inc, Mountain View, CA) was ﬁ  rst studied 
in clinical trials in rheumatoid arthritis and has shown in vitro 
activity in MM cells when co-cultured with BM stromal cells. 
The combination of SCIO-469 and Bortezomib demonstrated 
synergistic activity in vitro and in vivo (Hideshima et al 
2004b). A phase II trial of SCIO-469 alone or in combina-
tion with Bortezomib in patients with relapsed MM showed 
stable disease in 24% with single agent SCIO-469, with its 
combination with Bortezomib resulting in a response rate of 
32%, including response in patients in whom Bortezomib 
had failed (Siegel et al 2006).
Inhibitors of heat-shock protein 90: 17-
AAG, KOS-953, IPI-504
Heat shock protein 90 (HSP90) inhibitors such as geldana-
mycin and 17-allylamino-17-demethoxygeldanamycin (17-
AAG) bind to the N-terminal ATP-binding pocket of Hsp90 
and inhibit the stress induced anti-apoptotic response in MM 
cells and have demonstrated in vitro and in vivo cytotoxic 
activity alone and in combination with other agents active 
in MM, speciﬁ  cally Bortezomib (Mitsiades CS et al 2006). 
Phase I clinical trials of KOS 953—a 17AAG derivative—in 
MM have shown good tolerability with disease stabilization 
and minor response in patients with relapsed and refractory 
MM. Other HSP90 inhibitors include IPI-504, which is also 
being tested in a phase I clinical trial in MM and has excellent 
tolerability but no responses at doses tested to date (Rich-
ardson et al 2005b). Excitingly, KOS-953 combined with 
Bortezomib has demonstrated responses even in Bortezimib-
resistant patients in an ongoing phase I/II trial in patients 
with relapsed and refractory MM (Chanan-Khan et al 2005). 
Phase III trials of this combination are planned.
Monoclonal antibodies mainly active 
IN WM
Monoclonal anti-CD20 antibody: 
rituximab
Rituximab has become one of the main treatment options of 
patients with WM. Standard rituximab (4 weekly infusions 
of 375 mg/m2) has demonstrated at least a minor response in 
52% of patients (Gertz et al 2004). Four weekly rituximab 
treatments repeated at 3 months triggered response rates 
of 44%–48% (Dimopoulos et al 2003; Treon et al 2005a). 
Polymorphisms in the FcγRIIIA (CD16) receptor gene 
may affect response to rituximab in WM. The response to 
rituximab is delayed in most patients with a median time 
to partial response of 4 months and a median time to best 
response of 17 months (Treon et al 2005b). In addition, the 
IgM level may initially increase in response to rituximab, a 
phenomenon termed IgM ﬂ  are that occurs in about 54% of 
patients (Ghobrial et al 2004; Treon et al 2004a). These levels 
may persist for up to 4 months and do not indicate treatment 
failure, but may necessitate plasmapheresis to reduce hyper-
viscosity. Some patients receive maintenance therapy with 
rituximab. Although the impact of this regimen on the time 
to progression has not been determined speciﬁ  cally in WM, 
it has prolonged time to progression in patients in patients 
with other low-grade lymphomas who received rituximab 
maintenance compared to those who did not (van Oers et al 
2006). Rituximab may also be useful in treating patients 
with IgM autoantibody-related neuropathies (Renaud et al 
2006). The use of radioimmunotherapy such as iodine 131I-
tositumomab radioimmunotherapy in WM has been limited 
since the high level of BM involvement precludes their 
use. However, case reports have shown that these therapies 
may be effective in patients with WM who have <25% BM 
involvement (Tsai e al 2004).
Combinations of alkylating agents, nucleoside 
analogs, and rituximab
The addition of alkylating agents to nucleoside analogs 
is active against WM. For example, the combination of 
oral cyclophosphamide with subcutaneous cladribine in 
37 newly diagnosed patients achieved 84% PR or more, 
with a median duration of response of 36 months (Weber 
et al 2003b). The combination of ﬂ  udarabine and intrave-
nous cyclophosphamide in 11 previously treated patients 
resulted in 55% overall response. In another study of 49 
patients, the combination of ﬂ  udarabine plus cyclophos-
phamide induced 78% overall response, with median 
time to treatment failure was 27 months (Tamburini et al 
2005). Hematologic toxicity was commonly observed, 
and 3 patients died of treatment-related toxicities. A 
phase II clinical trial of 60 patients with WM treated with 
cyclophosphamide, rituximab, and dexamethasone (DRC) 
demonstrated an overall response rate of 70%, with 7% 
complete remission (Dimopoulos et al 2006). Treatment 
was well tolerated and the main toxicity observed was 
grade 3-4 neutropenia in 20% of the patients. The combina-
tion of rituximab, cladribine, and cyclophosphamide was 
tested in 17 previously untreated patients with WM and 
achieved at least a partial response in 94% of the patients, 
with complete response in 18% (Weber et al 2003b). The 
combination of rituximab and ﬂ  udarabine was evaluated Biologics: Targets & Therapy 2008:2(3) 427
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in 43 WM patients, with an overall response rate of 91% 
and CR of 7% (Treon et al 2004b). In another study, the 
combination of ﬂ  udarabine, cyclophosphamide and ritux-
imab (FCR) was tested in 21 patients with WM who had 
at least 1–2 prior regimens of therapy; overall response 
rate was 52%, with 5% complete remissions (Treon et al 
2006c). In MM, rituximab is being tested as a single agent 
or in combination with chemotherapeutic agents with some 
modest results of ∼64% minor responses and stable disease 
in one study (Moreau et al 2006).
Other monoclonal antibodies 
speciﬁ  cally active in WM
Anti-CD52 alemtuzumab-1H (Campath)
CD52 is highly expressed on WM cells in the BM, and 
alemtuzumab induces cytotoxicity of WM cells in vitro. A 
phase II study of alemtuzumab in 25 patients with relapsed 
WM or newly diagnosed untreated WM showed an overall 
response rate of 76%, including 8 (32%) partial responses 
and 11 (44%) minor responses. Hematological toxicities 
were common among previously treated (but not untreated) 
patients and included G3/4 neutropenia (39%); thrombocy-
topenia (18%); anemia (7%). G3/4 nonhematological toxic-
ity for all patients included dermatitis (11%); fatigue (7%); 
and infection (7%). CMV reactivation and infection was 
commonly seen among previously treated patients. Three 
patients died due to therapy-related complications (Hunter 
et al 2006).
Anti-CD70 antibody: SGN-70
Lymphoplasmacytic cells stimulate cell surface expression 
of TNF-family ligands through release of sCD27, which 
induces CD70 on mast cells. WM cells and cell lines highly 
express CD70 (Hatjiharissi et al 2006). Therefore, directly 
targeting CD70 using the fully humanized monoclonal anti-
body SGN-70 (Seattle Genetics, Inc., Bothell, WA) may 
represent a therapeutic option in WM. SGN-70 mediated 
signiﬁ  cant dose-dependent ADCC against WM cell and 
mast cells at concentrations of 0.1-20μg/ml. SCID-hu mice 
bearing WM cells were treated with SGN-70 (1 mg/kg, i.p., 
qOD), and serum IgM and sCD27 levels were measured to 
monitor for disease progression. SGN-70 initiated 6 weeks 
following tumor engraftment blocked tumor growth in 12/12 
treated mice, whereas all 5 untreated mice demonstrated 
disease progression (Hatjiharissi et al 2006). The results 
of these studies provide the framework for clinical trials to 
examine the therapeutic potential of the SGN-70 monoclonal 
antibody in WM.
Other monoclonal antibodies 
speciﬁ  cally active in MM
SGN-40
SGN-40 (Seattle Genetics, Inc.) is a humanized anti-CD40 
ligand. It has been shown that CD40 induces proliferation of 
MM cells by activating the PI3/Akt pathway and by inducing 
secretion of IL-6 and VEGF from BM stromal cells (Tai et al 
2005). Phase I study has been initiated demonstrating safety 
of this agent in MM with promising responses, and phase II 
trials are ongoing (Hussein et al 2006).
mAb antiCD40 receptor: HCD122
HCD122 is a a fully human, IgG1 antagonistic mAb target-
ing the CD40 receptor. A phase I trial has been conducted in 
MM patients and demonstrated that the Ab was safe, showing 
promising clinical activity in MM (Bensinger et al 2006).
Oligonucleotide antisense, 
Bcl-2 antisense
Bcl-2 inhibitor, G3139 (Oblimersen 
sodium)
Bcl-2 (Genasense, Genta Inc, Berkeley Heights, NJ) regu-
lates apoptosis and resistance to chemotherapeutic agents; 
it has therefore become an attractive target for anticancer 
therapy in a number of malignancies including MM and WM 
(Chanan-Khan et al 2003). In vitro studies have shown that 
Bcl-2 is expressed in several B cell malignancies cells, and 
that downregulation of Bcl-2 and increased cytotoxicity in 
MM and WM cells may be achieved with G3139 (Badros 
et al 2005). A Phase I/II clinical trial of G3139 was con-
ducted in patients with relapsed or relapsed/refractory WM 
showed favorable tolerability but little activity (Gertz et al 
2005). Similarly, a phase II study of G3139 in combination 
with dexamethasone and thalidomide has been initiated in 
relapsed MM patients: the combination is well tolerated, and 
the responses are promising (Badros et al 2005).
Other agents
Agents with preclinical activity in WM
AMD3100
Waldenström’s macroglobulinemia is characterized by wide-
spread involvement of the BM, and lymphadenopathy in 20% 
of the patients, implying continuous trafﬁ  cking of WM cells 
into and out of the BM and lymph nodes. The normal process 
of B-cell homing is regulated by cytokines, chemokines, 
and adhesion molecules (Lapidot et al 2005). One of the 
most extensively studied chemokines in migration is stromal Biologics: Targets & Therapy 2008:2(3) 428
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derived factor SDF-1 and its receptor CXCR4. We recently 
demonstrated that WM cells and patient samples highly express 
CXCR4, and that SDF-1 induced migration of WM cells, with 
rapid activation of signaling pathways downstream of CXCR4 
including pERK1/2, pAKT, and pPKC. The CXCR4 inhibitor 
AMD3100 (Genzyme, MA) inhibited migration of WM cells, 
as well as their adhesion to ﬁ  bronectin. Adhesion of WM cells 
to stromal cells confers resistance to apoptosis and induces 
proliferation. The combination of AMD3100 with Bortezomib 
signiﬁ  cantly enhances the cytotoxic effect of Bortezomib in 
the presence of stromal cells, possibly by interfering with 
adhesion of WM to stromal cells and thereby overcoming 
their protective effect (Ngo et al 2006). These studies provide 
the preclinical framework to study CXCR4 inhibitors in the 
regulation of homing and adhesion in WM.
Triterpenoids, CDDO, and CDDO-Im
2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and 
its methyl ester derivative (CDDO-Me) and imidazolide 
derivative (CDDO-Im) are synthetic triterpenoids derived 
from oleanolic acid. In vitro studies in primary WM samples 
showed that CDDO-Im inhibited cell proliferation and induced 
apoptosis in WM cells compared to normal B cells. There 
was evidence of PARP cleavage in a dose-dependent man-
ner, suggesting that CDDO-Im induced malignant cell death 
occurs through a caspase-dependent mechanism, and may have 
potential efﬁ  cacy in WM patients (Elsawa et al 2006).
Simvastatin and resveratrol
The antineoplastic activity of simvastatin and resveratrol in 
WM has been reported (Moreau et al 2007; Roccaro et al 
2008). The two compounds exert antiproliferative activity 
and induce apoptosis in WM. Interestingly, they target WM 
cells even in the presence of bone marrow microenviron-
ment and cytokines that are known to promote WM cell 
growth. Moreover, they both showed synergism when used 
in combination with other agents widely used in WM, such 
as dexamethasone and Bortezomib. Those preclinical in vitro 
data provide the framework for clinical trials of simvastatin 
or resveratrol in WM.
Sildenaﬁ  l citrate
Based on the clinical observation that patients receiving 
sildenaﬁ  l citrate had a decrease in their IgM (Treon et al 
2004c), a phase II trial of single agent sildenaﬁ  l citrate in 
patients with slowly progressing WM, who did not meet 
consensus eligibility for active therapy, was initiated. The 
purpose of the study was to delay time to progression in 
these patients. Thirty patients were treated on this study, and 
disease progression was suppressed in more than 50% of the 
patients. After 3 months of therapy, 63% showed a decrease 
in IgM levels and 17% showed a minor response. However, 
disease progression at 6 months of follow occurred in almost 
all the patients (Patterson et al 2006).
Imatinib mesylate
Imatinib mesylate (Gleevec) targets the microenvironment of 
WM through inhibition of stem cell factor signaling through 
CD117, which is expressed on WM and mast cells. A phase II 
trial of single agent imatinib is ongoing in patients with relapsed 
or refractory WM. Imatinib is given at 400 mg daily, with 
dose escalation to 600 mg after one month of therapy. After 
3 months of therapy, 6/13 (46.2%) of patients achieved MR. 
The main toxicities observed included cytopenias, edema, and 
hyperglycemia, leading to dose reductions in 31% patients and 
cessation of therapy in 23% patients (Treon et al 2006d).
TACI-Ig, Atacicept
Atacicept (TACI-Ig; ZymoGenetics, Seattle, WI) contains 
the soluble TACI receptor that binds to the cytokines BLyS 
and APRIL, members of the tumor necrosis factor family 
that promote B-cell survival. An open-label, dose-escalation 
Phase 1b study enrolled 16 patients with refractory or 
relapsed MM or active progressive WM. Sequential cohorts 
received one cycle of 5 weekly subcutaneous injections of 
atacicept at 2, 4, 7, or 10 mg/kg. Treatment with atacicept was 
well tolerated, and no dose limiting toxicity was observed. 
A biological response was observed in this heavily treated 
refractory population, with disease stabilization in 75% of 
the patients with WM (Rossi et al 2006).
Conclusions
In summary, the last decade has marked a new era in the treat-
ment of diseases characterized by monoclonal gammopaties. 
Indeed, a new paradigm shift has evolved utilizing novel 
therapeutic agents targeting the malignant clone and its bone 
marrow microenvironment. The combination of novel agents 
with chemotherapeutic drugs and/or glucocorticoids has dem-
onstrated high response rates with complete remission rates 
comparable to those achieved in the stem cell transplant set-
ting. This has been supported by in vitro and in vivo evidence 
showing the antitumor activity of those novel agents in MM, 
WM, as well as in other B cell maligancies. The future holds 
many more challenges for the treatment of MM and WM. 
These include combination of agents that achieve higher 
responses and longer survival, individualized therapies that 
are based on genetic and molecular abnormalities present in 
each patient, and clinical trials to test the beneﬁ  t of novel Biologics: Targets & Therapy 2008:2(3) 429
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agents in comparison and in addition to autologous stem cell 
transplantation, as well as other conventional approaches. 
Together, these therapies should lead to higher response 
rates, more durable duration of response, less toxicity and 
prolonged survival for patients, making plasma cell dyscra-
sias an increasingly chronic and treatable diseases.
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